Skip to main content

Advertisement

SpringerLink
Log in

Laser treatment for the management of genitourinary syndrome of menopause after breast cancer. Hope or hype?

  • Original Article
  • Published:
International Urogynecology Journal Aims and scope Submit manuscript

Abstract

Introduction and hypothesis

Fractional CO2 and vaginal erbium lasers have emerged as potential treatment options for genitourinary syndrome of menopause (GSM) in breast cancer (BC) survivors.

Methods

We conducted a systematic review of the literature to ascertain whether available evidence supports the efficacy and safety of laser treatment for GSM in BC patients. MEDLINE, Scopus and Cochrane Library databases were systematically searched from inception until March 2019 for studies on laser treatment for GSM in BC patients.

Results

We yielded six observational studies meeting the inclusion criteria. The studies were of moderate quality. Taken together, the studies suggest that laser treatment may significantly alleviate or resolve the GSM-related symptoms and improve sexual function. Furthermore, a significant increase of the vaginal health index was reported. Positive effect was maintained up to 12 months. The safety and tolerability profile is encouraging, given that no adverse effects were reported, while only few patients discontinued laser treatment, owing to reported discomfort.

Conclusions

Our findings suggest that lasers appear to be effective and practical treatment options in BC survivors suffering from GSM. Evidence concerning long-term effects is lacking. The rationale for repeated treatment remains uncertain. Randomized controlled trials that collate different frequencies, intensities and durations are warranted to ascertain a dose-response relationship and adherence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.

    Article  Google Scholar 

  2. Howlade N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975–2008. Bethesda: National Cancer Institute; 2011.

    Google Scholar 

  3. Guo F, Kuo YF, Shih YCT, Giordano SH, Berenson AB. Trends in breast cancer mortality by stage at diagnosis among young women in the United States. Cancer. 2018;124:3500–9.

    Article  Google Scholar 

  4. Sousa MS, Peate M, Jarvis S, Hickey M, Friedlander M. A clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapy. Ther Adv Med Oncol. 2017;9:269–85.

    Article  Google Scholar 

  5. Runowicz CD, Leach CR, Henry NL, et al. American Cancer Society/American Society of Clinical Oncology breast cancer survivorship care guideline. CA Cancer J Clin. 2016;66:43–73.

    Article  Google Scholar 

  6. Palma F, Volpe A, Villa P, Cagnacci A. Vaginal atrophy of women in potmenopause. Results from a multicentric observational study: the AGATA study. Maturitas. 2016;83:40–4.

    Article  CAS  Google Scholar 

  7. Lester J, Pahouja G, Andersen B, Lustberg M. Atrophic vaginitis in breast cancer survivors: a difficult survivorship issue. J Pers Med. 2015;5:50–66.

    Article  Google Scholar 

  8. Biglia N, Bounous VE, D’Alonzo M, et al. Vaginal atrophy in breast cancer survivors: attitude and approaches among oncologists. Clin Breast Cancer. 2017;17:611–7.

    Article  Google Scholar 

  9. Daly B, Olopade OI, Hou N, Yao K, Winchester DJ, Huo D. Evaluation of the quality of adjuvant endocrine therapy delivery for breast cancer in United States. JAMA Oncol. 2017;3:928–35.

    Article  Google Scholar 

  10. Goss PE, Ingle JN, Pritchard KI, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med. 2016;375:209–19.

    Article  CAS  Google Scholar 

  11. Faubion SS, Stuenkel CA, Chism LA, et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from the North American Menopause Society and the International Society for the Study of Women’s. Sexual Health Menopause. 2018;25:596–608.

    PubMed  Google Scholar 

  12. ACOG Committee Opinion No. 659: the use of vaginal estrogen in women with history of estrogen-dependent breast cancer. Obstet Gynecol. 2016;127:93–96.

  13. Cruz VL, Steiner ML, Pompei LM, et al. Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women. Menopause. 2018;25:21–8.

    Article  Google Scholar 

  14. Qureshi AA, Tenenbaum MM, Myckatyn TM. Nonsurgical vulvovaginal rejuvenation with radiofrequency and laser devices: a literature review and comprehensive update for aesthetic surgeons. Aesthet Surg J. 2018;38:302–11.

    Article  Google Scholar 

  15. Liberati A, Altman DG, Tetzlaff J, et al. The prisma statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62:1–34.

    Article  Google Scholar 

  16. Lim K, Nini E, Forestier D, et al. Methodological index for non-randomized studies (MINORS): development and validation of a new instrument. ANZ J Surg. 2003;73:712Y716.

    Article  Google Scholar 

  17. Salvatore S, Nappi RE, Zerbinati N, et al. A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study. Climacteric. 2014;17:363–9.

    Article  CAS  Google Scholar 

  18. Gittens P, Mullen G. The effects of fractional microablative CO2 laser therapy on sexual function in postmenopausal women and women with a history of breast cancer treated with endocrine therapy. J Cosmet Laser Ther. 2018;8:1–5.

    Google Scholar 

  19. Becorpi A, Campisciano G, Zanotta N, et al. Fractional CO2 laser for genitourinary syndrome of menopause in breast cancer survivors: clinical, immunological, and microbiological aspects. Lasers Med Sci. 2018;33:1047–54.

    Article  Google Scholar 

  20. Pagano T, De Rosa P, Vallone R, et al. Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective study. Menopause. 2018;25:657–62.

    Article  Google Scholar 

  21. Gambacciani M, Levancini M. Vaginal erbium laser as second-generation thermotherapy for the genitourinary syndrome of menopause: a pilot study in breast cancer survivors. Menopause. 2017;24:316–9.

    Article  Google Scholar 

  22. Pieralli A, Fallani MG, Becorpi A, et al. Fractional CO2 laser for vulvovaginal atrophy (VVA) dyspareunia relief in breast cancer survivors. Arch Gynecol Obstet. 2016;294:841–6.

    Article  CAS  Google Scholar 

  23. Mothes AR, Runnenbaum M, Runnenbaum IB. Ablative dual-phase erbium: YAG laser treatment of atrophy-related vaginal symptoms in post-menopausal breast cancer survivors omitting hormonal treatment. J Cancer Res Clin Oncol. 2018;144:955–60.

    Article  CAS  Google Scholar 

  24. Derzko C, Elliot S, Lam W. Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy. Curr Oncol. 2007;14:20–40.

    Article  Google Scholar 

  25. Salvatore S, Leone Roberti Maggiore U, et al. Histological study on the effects of microablative fractional CO2 laser on atrophic vaginal tissue: an ex vivo study. Menopause. 2015;22:845–9.

    Article  Google Scholar 

  26. Cruz VL, Steiner ML, Pompei LM, et al. Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women. Menopause. 2017;25:21–8.

    Article  Google Scholar 

  27. Gaspar A, Brandi H, Gomez V, Luque D. Efficacy of erbium: YAG laser treatment compared to topical estriol treatment for symptoms of genitourinary syndrome of menopause. Lasers Surg Med. 2017;49:160–8.

    Article  Google Scholar 

  28. Flint R, Cardoso T, Grigoriadis T, Rantell A, Pitsouni E, Athanasiou S. Rationale and design for fractional microablative CO2 laser versus non-ablative erbium : YAG laser for the treatment of genitourinary syndrome of menopause: a non-inferiority, single-blind randomized controlled trial. Climacteric. 2019;24:1–5.

    Google Scholar 

Download references

Funding

We certify that no party has a direct interest in the results of the research and that no benefit will be conferred to us or any organization with which we are associated.

Author information

Author notes

  1. Anastasios Tranoulis, Dimitra Georgiou and Lina Michala contributed equally to this work.

Authors and Affiliations

  1. Department of Obstetrics and Gynaecology, Guy’s and St Thomas’ NHS Foundation, King’s College, Westminster Bridge Rd, Lambeth, London, SE1 7EH, UK

    Anastasios Tranoulis

  2. Department of Obstetrics and Gynaecology, Chelsea and Westminster NHS Trust, Imperial College, London, UK

    Dimitra Georgiou

  3. First Department of Obstetrics and Gynaecology, Alexandra Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

    Lina Michala

Authors
  1. Anastasios Tranoulis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dimitra Georgiou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lina Michala
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anastasios Tranoulis.

Ethics declarations

Conflicts of interest

None.

Details of ethics approval

None needed, as this is a systematic review.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tranoulis, A., Georgiou, D. & Michala, L. Laser treatment for the management of genitourinary syndrome of menopause after breast cancer. Hope or hype?. Int Urogynecol J 30, 1879–1886 (2019). https://doi.org/10.1007/s00192-019-04051-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00192-019-04051-3

Keywords

Search

Navigation